Compare
AbbVie vs Alnylam Pharmaceuticals (ABBV vs ALNY)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Alnylam Pharmaceuticals (ALNY) -64.1%; so far this year the figures are +27.5% and -60.8%.
AbbVie is the larger company by market value, about 24.6 times the size of Alnylam Pharmaceuticals.
On trailing earnings, ABBV trades at 50.1 times and ALNY at 66.9 times.
Revenue grew +10.7% at ABBV and +65.2% at ALNY over the last year.
ABBV yields 2.38%. ALNY pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | ALNY | |
|---|---|---|
| Price | $291.31 | $155.94 |
| 1-day | +1.07% | -0.46% |
| YTD | +27.49% | -60.78% |
| 1 year | +34.39% | -64.12% |
| 3 years | +104.47% | -0.68% |
| Market cap | $514.9B | $20.9B |
| P/E | 50.1 | 66.9 |
| P/S | 7.80 | 5.62 |
| P/B | — | 5.80 |
| Revenue growth | +10.70% | +65.20% |
| EPS growth | +340.20% | — |
| Gross margin % | 73.7 | 81.8 |
| Net margin % | 15.7 | 8.4 |
| ROE % | — | 8.7 |
| Debt / equity | — | 0.19 |
| FCF yield % | 3.7 | 2.2 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 0.47 |
| RSI (14) | 59.7 | 21.8 |
| Technical rating |